Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111891
Status:
COMPLETED
Last Update Posted:
2017-02-17
First Post:
2005-05-26
Brief Title:
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia 0524A-032
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Dose Ranging Study to Evaluate the Tolerability of MK0524 Niacin Laropiprant and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients andor Normal Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia
Detailed Description:
The duration of treatment is 7 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_032 | None | None | None |
| MK0524A-032 | None | None | None |